Praktyczne aspekty zastosowania lakozamidu u pacjentów z padaczką Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 20, 2022
Słowa kluczowe:
lakozamid, padaczka, leczenie
##plugins.themes.bootstrap3.article.main##
Abstrakt
Lakozamid to lek przeciwpadaczkowy III generacji zaaprobowany do leczenia napadów ogniskowych z wtórnym uogólnieniem lub bez niego jako monoterapia i terapia dodana. Ogólnie jest dobrze tolerowany i ma niski potencjał interakcji lekowych, w tym z lekami antykoncepcyjnymi. Lakozamid jest wartościową opcją terapeutyczną u chorych z nowo zdiagnozowaną padaczką.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Kopka , M. (2022). Praktyczne aspekty zastosowania lakozamidu u pacjentów z padaczką . Medycyna Faktów , 15(2(55), 190-194. https://doi.org/10.24292/01.MF.0222.11
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Chang BS, Lowenstein DH. Epilepsy. N Engl J Med. 2003; 349: 1257-66.
2. Kwan P, Arzimanoglou A, Berg AT et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010; 51: 1069-77.
3. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000; 342: 314-9.
4. Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012; 11: 792-802.
5. Errington AC, Stöhr T, Heers C et al. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol. 2008; 73(1): 157-69.
6. Thomas D, Horstmann R, Scharfenecker U et al. Lacosamide has low potential for drug-drug-interaction. Poster presented at: The American Society of Consultant Pharmacists 38th Annual Meeting, Philadelphia, PA, November 14–17, 2007.
7. Cawello W, Kropeit D, Schiltmeyer B et al. Food does not affect the pharmacokinetics of SPM 927 (Abstract). Epilepsia. 2004; 45(suppl 7): 307.
8. Horstmann R, Bonn R, Cawello W et al. Basic clinical pharmacological investigations of the new antiepileptic drug SPM927 (Abstract). Epilepsia. 2002; 43(suppl 7): 188.
9. Kropeit D, Scharfenecker U, Schiltmeyer B et al. Lacosamide has low potential for drug-drug interaction (Abstract 851). J Pain. 2006; 7: S63.
10. Ben-Menachem E, Biton V, Jatuzis D et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007; 48: 1308-17.
11. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M et al; SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia. 2009; 50(3): 443-53.
12. Chung S, Sperling MR, Biton V et al; SP754 Study Group. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010; 51(6): 958-67.
13. Chung S, Ben-Menachem E, Sperling MR et al. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials. CNS Drugs. 2010; 24(12): 1041-54.
14. Sake JK, Hebert D, Isojärvi J et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs. 2010; 24(12): 1055-68.
15. Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: Effect of past treatment history. Neurology. 2008; 70: 54-65.
16. Cramer JA, Ben Menachem E, French J. Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilepsy Res. 2001; 47: 17-25.
17. Husain A, Chung S, Faught E et al. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial. Epilepsia. 2012; 53: 521-8.
18. Rosenfeld W, Fountain NB, Kaubrys G et al. Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a longterm open-label extension trial of up to 8 years. Epilepsy Behav. 2014; 41: 164-70.
19. Rosenow F, Kelemen A, Ben-Menachem E et al. Long-term adjunctive lacosamide treatment in patients with partial-onset seizures. Acta Neurol Scand. 2016; 133: 136-44.
20. Runge U, Arnold S, Brandt C et al. A noninterventional study evaluating the eff ectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: the VITOBA study. Epilepsia. 2015; 56: 1921-30.
21. Villanueva V, Lopez-Gomariz E, Lopez-Trigo J et al. Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA. Epilepsy Behav. 2012; 23: 298-304.
22. Baulac MJ, Rosenow F, Toledo M et al. Efficacy and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly-diagnosed epilepsy: a phase 3 randomised double-blind non-inferiority trial. Lancet Neurol. 2016; 16: 43-54.
23. Wechsler RT, Li G, French J et al. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study. Epilepsia. 2014; 55: 1088-98.
24. Del Bianco C, Placidi F, Liguori C et al. Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study. Epilepsy Behav. 2019; 94: 178-82.
25. Lattanzi S, Cagnetti C, Foschi N et al. Lacosamide monotherapy for partial onset seizures. Seizure. 2015; 27: 71-4.
26. Wilner AN, Sharma BK, Soucy A et al. Common comorbidities in women and men with epilepsy and the relationship between number of comorbidities and health plan paid costs in 2010. Epilepsy Behav. 2014; 32: 15-20.
27. Casciato S, Quarato PP, Gialluisi A et al. Lacosamide as first add-on or conversion monotherapy: A retrospective real-life study. Epilepsy Behav. 2021; 122: 108-28.
28. Villanueva V, Giráldez BG, Toledo M et al. Lacosamide monotherapy in clinical practice: a retrospective chart review. Acta Neurol Scand. 2018; 138(3): 186-94.
29. Lachuer C, Corny J, Bézie Y et al. Complete atrioventricular block in an elderly patient treated with low-dose lacosamide. Cardiovasc Toxicol.
2018; 18(6): 579-82.
30. Bialer M, Johannessen SI, Kupferberg HJ et al. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 2004; 61: 1-48.
31. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ. 1996; 313: 1169-74.
32. Yang C, Peng Y, Zhang L et al. Safety and Tolerability of Lacosamide in Patients With Epilepsy: A Systematic Review and Meta-Analysis. Front Pharmacol. 2021; 12: 694381. http://doi.org/10.3389/fphar.2021.694381.
33. Rejdak K, Rola R, Mazurkiewicz-Bełdzińska M et al. Diagnostyka i leczenie padaczki – wytyczne Sekcji Padaczki Polskiego Towarzystwa Neurologicznego. Pol Przegl Neurol. 2020; 16(3): 129-44.
34. https://indeks.mp.pl/leki/desc.php?id=17040 (access: 11.04.2022).
35. Sander JW. The use of antiepileptic drugs – principles and practice. Epilepsia. 2004; 45(suppl 6): 28-34.
2. Kwan P, Arzimanoglou A, Berg AT et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010; 51: 1069-77.
3. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000; 342: 314-9.
4. Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012; 11: 792-802.
5. Errington AC, Stöhr T, Heers C et al. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol. 2008; 73(1): 157-69.
6. Thomas D, Horstmann R, Scharfenecker U et al. Lacosamide has low potential for drug-drug-interaction. Poster presented at: The American Society of Consultant Pharmacists 38th Annual Meeting, Philadelphia, PA, November 14–17, 2007.
7. Cawello W, Kropeit D, Schiltmeyer B et al. Food does not affect the pharmacokinetics of SPM 927 (Abstract). Epilepsia. 2004; 45(suppl 7): 307.
8. Horstmann R, Bonn R, Cawello W et al. Basic clinical pharmacological investigations of the new antiepileptic drug SPM927 (Abstract). Epilepsia. 2002; 43(suppl 7): 188.
9. Kropeit D, Scharfenecker U, Schiltmeyer B et al. Lacosamide has low potential for drug-drug interaction (Abstract 851). J Pain. 2006; 7: S63.
10. Ben-Menachem E, Biton V, Jatuzis D et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007; 48: 1308-17.
11. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M et al; SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia. 2009; 50(3): 443-53.
12. Chung S, Sperling MR, Biton V et al; SP754 Study Group. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010; 51(6): 958-67.
13. Chung S, Ben-Menachem E, Sperling MR et al. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials. CNS Drugs. 2010; 24(12): 1041-54.
14. Sake JK, Hebert D, Isojärvi J et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs. 2010; 24(12): 1055-68.
15. Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: Effect of past treatment history. Neurology. 2008; 70: 54-65.
16. Cramer JA, Ben Menachem E, French J. Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilepsy Res. 2001; 47: 17-25.
17. Husain A, Chung S, Faught E et al. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial. Epilepsia. 2012; 53: 521-8.
18. Rosenfeld W, Fountain NB, Kaubrys G et al. Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a longterm open-label extension trial of up to 8 years. Epilepsy Behav. 2014; 41: 164-70.
19. Rosenow F, Kelemen A, Ben-Menachem E et al. Long-term adjunctive lacosamide treatment in patients with partial-onset seizures. Acta Neurol Scand. 2016; 133: 136-44.
20. Runge U, Arnold S, Brandt C et al. A noninterventional study evaluating the eff ectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: the VITOBA study. Epilepsia. 2015; 56: 1921-30.
21. Villanueva V, Lopez-Gomariz E, Lopez-Trigo J et al. Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA. Epilepsy Behav. 2012; 23: 298-304.
22. Baulac MJ, Rosenow F, Toledo M et al. Efficacy and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly-diagnosed epilepsy: a phase 3 randomised double-blind non-inferiority trial. Lancet Neurol. 2016; 16: 43-54.
23. Wechsler RT, Li G, French J et al. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study. Epilepsia. 2014; 55: 1088-98.
24. Del Bianco C, Placidi F, Liguori C et al. Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study. Epilepsy Behav. 2019; 94: 178-82.
25. Lattanzi S, Cagnetti C, Foschi N et al. Lacosamide monotherapy for partial onset seizures. Seizure. 2015; 27: 71-4.
26. Wilner AN, Sharma BK, Soucy A et al. Common comorbidities in women and men with epilepsy and the relationship between number of comorbidities and health plan paid costs in 2010. Epilepsy Behav. 2014; 32: 15-20.
27. Casciato S, Quarato PP, Gialluisi A et al. Lacosamide as first add-on or conversion monotherapy: A retrospective real-life study. Epilepsy Behav. 2021; 122: 108-28.
28. Villanueva V, Giráldez BG, Toledo M et al. Lacosamide monotherapy in clinical practice: a retrospective chart review. Acta Neurol Scand. 2018; 138(3): 186-94.
29. Lachuer C, Corny J, Bézie Y et al. Complete atrioventricular block in an elderly patient treated with low-dose lacosamide. Cardiovasc Toxicol.
2018; 18(6): 579-82.
30. Bialer M, Johannessen SI, Kupferberg HJ et al. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 2004; 61: 1-48.
31. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ. 1996; 313: 1169-74.
32. Yang C, Peng Y, Zhang L et al. Safety and Tolerability of Lacosamide in Patients With Epilepsy: A Systematic Review and Meta-Analysis. Front Pharmacol. 2021; 12: 694381. http://doi.org/10.3389/fphar.2021.694381.
33. Rejdak K, Rola R, Mazurkiewicz-Bełdzińska M et al. Diagnostyka i leczenie padaczki – wytyczne Sekcji Padaczki Polskiego Towarzystwa Neurologicznego. Pol Przegl Neurol. 2020; 16(3): 129-44.
34. https://indeks.mp.pl/leki/desc.php?id=17040 (access: 11.04.2022).
35. Sander JW. The use of antiepileptic drugs – principles and practice. Epilepsia. 2004; 45(suppl 6): 28-34.